TITLE

A counseling strategy was better than usual care for adopting and maintaining physical activity in type 2 diabetes

PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article discusses whether counseling strategy is better than usual care for adopting and maintaining long-term physical activity in patients with type 2 diabetes mellitus. 182 patients were allocated to a counseling strategy, which consisted of usual care plus a 30-minute structured counseling session recommending physical activity with a discussion of 7 points to promote exercise using a checklist. 158 patients were allocated to usual care. More patients in the counseling-strategy group achieved target energy expenditure through voluntary physical activity than did those in the usual-care group.
ACCESSION #
11533504

 

Related Articles

  • The next step for insulin-resistant diabetics. R.M.D. // Cortlandt Forum;3/25/96, Vol. 9 Issue 3, p65 

    Discusses the advantages of adding oral agents to the regular medication regimen for an insulin-resistant patient with type II diabetes. Likelihood that such patients will not respond to oral agents.

  • Metformin is effective therapy in patients with non-insulin-dependent diabetes mellitus. Dale, David C.; Federman, Daniel M. // Cortlandt Forum;11/25/96, Vol. 9 Issue 11, p25 

    Looks into metformin as the drug of choice for patients with non-insulin-dependent diabetes mellitus. Mechanism of action; Results of trial of patients with inadequate glycemic control; Side effects.

  • Once-daily insulin-sparing sulfonylurea for noninsulin-dependent diabetics.  // Modern Medicine;Feb96, Vol. 64 Issue 2, p37 

    Reports that the United States Food and Drug Administration has cleared glimepiride (Amaryl) an insulin-sparing sulfonylurea for non-insulin dependent diabetics for marketing. Recommended dose; Side effects; Contraindications.

  • Glimepiride is an effective sulfonylurea for noninsulin-dependent diabetes.  // Modern Medicine;Dec96, Vol. 64 Issue 12, p54 

    Summarizes the study `A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents,' by R.B. Goldberg and colleagues, published in the August 1996 issue of `Diabetes Care.' Safety and effectiveness of glimepiride as glucose-lowering agent for...

  • Troglitazone lowers plasma glucose levels by as much as 20%.  // Modern Medicine;Mar98, Vol. 66 Issue 3, p22 

    Discusses the abstract of the article `Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus,' by D.G. Maggs, T.H. Buchanan et al, which appeared in the February 1, 1998 issue of `Annual of Internal Medicine.'

  • Efficacy of Metformin in the Treatment of NIDDM. Johansen, Klaus // Diabetes Care;Jan1999, Vol. 22 Issue 1, p33 

    Focuses on a study which compared the efficacy of metformin with sulfonylurea in the treatment of non-insulin-dependent diabetes mellitus. Research design and methods; Results; Conclusions.

  • Something old, something new. Portyansky, Elena // Drug Topics;5/5/97, Vol. 141 Issue 9, p39 

    Reports on issues discussed in a recent Type II diabetes teleconference sponsored by Bristol-Meyers Squibb. Fasting glucose level of 125 mg/dl considered as diabetes; Importance of strict glucose control to manage diabetes; Insulin sensitizers as focus of therapy; Sulfonylureas as mainstay of...

  • Gatifloxacin.  // Reactions Weekly;3/4/2006, Issue 1091, p12 

    Presents a case report involving the use of gatifloxacin for the treatment of leg ulcer. With reference to a study conducted by J. A. Stading, A. W. Y. Chock, M. Z. Skrabal and M. A. Faulkner, published in the November 2005 issue of the "American Journal of Health-System Pharmacy"; Development...

  • DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE Study. Kazufumi Nakamura; Hiroki Oe; Hajime Kihara; Kenei Shimada; Shota Fukuda; Kyoko Watanabe; Tsutomu Takagi; Kei Yunoki; Toru Miyoshi; Kumiko Hirata; Junichi Yoshikawa; Hiroshi Ito // Cardiovascular Diabetology;2014, Vol. 13 Issue 1, p1 

    Background Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics